plasma protein fraction (human) protenate liquid
hyland, division of baxter healthcare corporation - plasma protein fraction (human) - liquid - 5g - plasma protein fraction (human) 5g - blood derivatives
settle mycobacterium cell wall fraction immunostimulant
novavive australasia pty ltd - mycobacterium cell wall fraction; gentamicin - parenteral liquid/solution/suspension - mycobacterium cell wall fraction ungrouped active 1.0 mg/ml; gentamicin antibiotic other 30.0 ug/ml - immunotherapy - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - equine respiratory tract infections vira | infections of viral origin
acticor 7 dr-t - defibrillator, implantable, automatic, dual-chamber
biotronik australia pty ltd - 37265 - defibrillator, implantable, automatic, dual-chamber - a dual chamber, rate adaptive icd with home monitoring functions, max. shock energy 40j and df4/is-1 connector. biocompatible titanium housing is hermetically sealed and serves as a potential antipole during shock delivery or in the case of unipolar lead configuration. ellipsoid shape facilitates implantation in the pectoral muscle area. the connections for bipolar pacing, sensing and shock delivery are found in the header. mr conditional. acticor 7 dr-t belongs to a family of implantable cardioverter-defibrillators (icds). the primary objective of the therapy is to prevent sudden cardiac death. furthermore, the device is capable of treating bradycardia arrhythmias. the implantation of an icd is a symptomatic therapy with the following objectives: ?termination of spontaneous ventricular fibrillation (vf) through shock delivery ?termination of spontaneous ventricular tachycardia (vt) through antitachycardia pacing (atp); in case of ineffective atp or hemodynamically not tolerated vts, with shock delivery ?comp
bacticorten-b lotion antibiotic lotion with anti-inflammatory, anaesthetic & bitterant
dechra veterinary products (australia) pty. ltd. - neomycin sulfate; lignocaine hydrochloride; hydrocortisone; denatonium benzoate - topical cream, ointment, paste, gel, lotion - neomycin sulfate antibiotic active 5.0 mg/ml; lignocaine hydrochloride caine active 10.0 mg/ml; hydrocortisone steroid-glucocorticoid active 5.0 mg/ml; denatonium benzoate carbamate other 0.2 mg/ml - dermatological preps. - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - dermatoses | infections of the skin | pruritis | abscesses | allergic skin disorder | anal sacculitis | fungal | gingivitis | gram negative bacteria | gram positive bacteria | post-parturient infections | pyoderma | septicaemia | yeast
fractional co2 laser therapy systems,fg900 - dermatological carbon dioxide laser system
compliance management solutions - 61473 - dermatological carbon dioxide laser system - the fractional co2 laser therapy systems is indicated for treatment of skin diseases, including seborrheic keratosis, syringoma, verruca vulgaris, flat wart, eyelid xanthoma, melanocytic nevus.
forceps, dental, tooth extraction
dentavision pty ltd - 35552 - forceps, dental, tooth extraction - extraction of teeth.
forceps, dental, tooth extraction
collaborative orthodontics pty ltd - 35552 - forceps, dental, tooth extraction - extraction forcep
forceps, dental, tooth extraction
amalgadent dental pty ltd - 35552 - forceps, dental, tooth extraction - extraction forcep for teeth removal
octaplas- human plasma proteins solution
octapharma usa inc - plasma protein fraction (human) (unii: 6d53g0fd0z) (plasma protein fraction (human) - unii:6d53g0fd0z) - plasma protein fraction (human) 11.5 g in 200 ml - octaplas is a solvent / detergent (s/d) treated, pooled human plasma indicated for: - replacement of multiple coagulation factors in patients with acquired deficiencies - due to liver disease - undergoing cardiac surgery and liver transplantation - plasma exchange in patients with thrombotic thrombocytopenic purpura (ttp) do not use octaplas in patients with: - iga deficiency - severe deficiency of protein s - history of hypersensitivity to fresh frozen plasma (ffp) or to plasma-derived products including any plasma protein - history of hypersensitivity reaction to octaplas risk summary animal reproduction studies have not been conducted with octaplas. it is not known whether octaplas can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. octaplas should be given to a pregnant woman only if clearly needed. the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background
octaplas- human plasma proteins solution
octapharma usa inc - plasma protein fraction (human) (unii: 6d53g0fd0z) (plasma protein fraction (human) - unii:6d53g0fd0z) - plasma protein fraction (human) 11.5 g in 200 ml - octaplas is a solvent / detergent (s/d) treated, pooled human plasma indicated for: - replacement of multiple coagulation factors in patients with acquired deficiencies - due to liver disease - undergoing cardiac surgery and liver transplantation - plasma exchange in patients with thrombotic thrombocytopenic purpura (ttp) do not use octaplas in patients with: - iga deficiency - severe deficiency of protein s - history of hypersensitivity to fresh frozen plasma (ffp) or to plasma-derived products including any plasma protein - history of hypersensitivity reaction to octaplas risk summary animal reproduction studies have not been conducted with octaplas. it is not known whether octaplas can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. octaplas should be given to a pregnant woman only if clearly needed. the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background